搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
Le Lézard
2 小时
Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical ...
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative ...
生物通
14 小时
我国学者在肺癌脑转移靶向治疗耐药研究方面取得进展
在国家自然科学基金项目(批准号:82072784、82072785、82273304、82303437)等资助下,复旦大学附属华山医院毛颖教授、花玮教授和迟喻丹研究员团队在免疫逃逸参与肺癌脑转移靶向治疗耐药研究方面取得进展。研究成果以“通过CTLA4 ...
The American Journal of Managed Care
20 小时
FDA Approves Imatinib Oral Solution for Treatment of Various Cancers
The oral solution offers precise dosing, benefiting patients with swallowing difficulties or requiring tailored dosing.
Cure Today
1 天
Focusing Research on T-Cell ALL to Further Treatment Options
An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.
Too Old to Operate
1 天
Asciminib improves outcomes in chronic myeloid leukemia
In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia (CML), asciminib demonstrated a ...
Pharmaceutical Technology
1 天
Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers
The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...
1 天
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Targeted Oncology
1 天
FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers
Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.
Cure Today
2 天
Understanding Treatment Sequences in Managing R/R CLL
For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how ...
GlobalData on MSN
2 天
MSD’s WELIREG approved by NMPA to treat VHL disease-associated tumours
The approval is based on the Phase II LITESPARK-004 trial's objective response rate and median duration of response outcomes.
Managed Healthcare Executive
2 天
ICER to Assess Sanofi’s Tolebrutinib for Secondary Progressive MS
The Institute for Clinical and Economic Review (ICER) has announced plans to assess the clinical efficacy and value of ...
Targeted Oncology
3 天
Behind the Phase 1 Study of TAR-210 in FGFR-Altered NMIBC
Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈